Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of fucoidan/fucoxanthin/L-carnitine combinaed therapy in patients with diabetic kidney disease.
Participants were randomly assigned in a 1:1 ratio to either the Treatment Group or the Control Group. The primary objective is to investigate whether fucoidan/fucoxanthin/L-carnitine/Zinc yeast combinaed therapy can significantly improve albuminuria or renal function after a treatment period of 12 weeks. Secondary outcomes include evaluating the safety profile and potential side effects of the intervention.
It is hypothesized that the intervention will show a beneficial effect on albuminuria compared to the control group. in patients withdiabetic kidney disease.
調査の概要
状態
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Taipei、台湾、116
- Wanfang Hospital, Taipei Medical Univeristy
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Documented glycated hemoglobin (HbA1c) > 6.5% with current use of anti-diabetic medication.
- A urine albumin-to-creatinine ratio (UACR) greater than 30 mcg/mg.
Exclusion Criteria:
- Age younger than 20 years.
- Inability to understand or provide written informed consent.
- Absence of regular treatment for diabetes mellitus.
- Medication non-compliance, defined as completing less than 50% of the prescribed formula (FFL) treatment.
- Newly diagnosed glomerulonephritis during the study period.
- Loss to follow-up, defined as failure to complete all laboratory tests required for outcome assessment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:FFL group
Participants received the marine-derived formula FFL (a combination of low-molecular-weight oligo-fucoidan, fucoxanthin-containing extract, and L-carnitine) as an adjunctive therapy to their existing standard-of-care for diabetic kidney disease.
The daily dose consisted of 4 capsules per day, delivering a total of 740 mg of oligo-fucoidan, 1200 mg of fucoxanthin, and 120 mg of L-carnitine.
The intervention was maintained for a total duration of 12 weeks while keeping their baseline anti-diabetic and renoprotective medications unchanged.
|
Combined marine-derived formulation administered orally in capsule form.
Each day, participants took 4 capsules, providing a total daily dose of 740 mg of low-molecular-weight oligo-fucoidan, 1200 mg of fucoxanthin-containing extract, and 120 mg of L-carnitine.
The intervention was used as an add-on therapy to standard diabetic kidney disease care for a total duration of 12 weeks.
|
|
介入なし:Control group
Participants continued their optimized standard-of-care treatment for diabetic kidney disease (including SGLT2 inhibitors and ACEIs/ARBs) for 12 weeks.
No active capsules or placebos were administered to this group.
All baseline anti-diabetic and blood pressure medications were required to remain stable and unchanged throughout the study period.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR)
時間枠:Baseline and Week 12
|
The UACR was assessed via random spot urine collection.
The primary outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekUACR-BaselineUACR)/BaselineUACR\) * 100%.
A negative percentage indicates a reduction in albuminuria (improvement).
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
時間枠:Baseline and Week 12
|
Serum creatinine was measured and eGFR was calculated using the 2021 CKD-EPI creatinine equation.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekeGFR-BaselineeGFR)/BaselineeGFR\) * 100%.
This parameter was evaluated to monitor for any acute hemodynamically-induced decline (eGFR dip) upon treatment initiation.
|
Baseline and Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage Change From Baseline in Glycated Hemoglobin (HbA1c)
時間枠:Baseline and Week 12
|
Blood samples were collected to analyze HbA1c levels for evaluating glycemic control.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekHbA1c-BaselineHbA1c)/BaselineHbA1c\) * 100%.
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
時間枠:Baseline and Week 12
|
Fasting lipid profiles were analyzed to evaluate lipid metabolism.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekLDL-C-BaselineLDL-C)/BaselineLDL-C\) * 100%.
|
Baseline and Week 12
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Lin SL, Tsai WL, Chen TW, Chen TH. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant. 2009 Oct;24(10):3042-9. doi: 10.1093/ndt/gfp258. Epub 2009 Jun 2.
- Chen YC, Cheng CY, Liu CT, Sue YM, Chen TH, Hsu YH, Hwang PA, Chen CH. Alleviative effect of fucoxanthin-containing extract from brown seaweed Laminaria japonica on renal tubular cell apoptosis through upregulating Na+/H+ exchanger NHE1 in chronic kidney disease mice. J Ethnopharmacol. 2018 Oct 5;224:391-399. doi: 10.1016/j.jep.2018.06.023. Epub 2018 Jun 18.
- Chen TH, Liu CT, Cheng CY, Sue YM, Huang NJ, Chen CH. Oligosaccharides Ameliorate Acute Kidney Injury by Alleviating Cluster of Differentiation 44-Mediated Immune Responses in Renal Tubular Cells. Nutrients. 2022 Feb 11;14(4):760. doi: 10.3390/nu14040760.
- Chen CH, Sue YM, Cheng CY, Chen YC, Liu CT, Hsu YH, Hwang PA, Huang NJ, Chen TH. Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway. Sci Rep. 2017 Jan 18;7:40183. doi: 10.1038/srep40183.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- N202409023
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。